...
10.13.06
Indication:
Weight gain and glycemic control
Source:
Diabetes Care, August 2006;29(8):1826-32.
Research:
Thirty-seven subjects with type 2 diabetes were evaluated in a 40-week study. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for three months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1000 micrograms Cr as CrPic (n = 17) for six months. Body composition, insulin sensitivity and glycemic control were determined at baseline, end of the three-month single-blind placebo phase and end of study.
Results:
Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight, percent body fat, and total abdominal fat. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass, GHb and free fatty acids, as opposed to sulfonylurea/placebo. According to researchers, this study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group.